Forest Laboratories to Acquire Clinical Data, Inc.

Forest LaboratoriesForest Laboratories, Inc. (Forest) (NYSE: FRX) and Clinical Data, Inc. (Clinical Data) (NASDAQ: CLDA) have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics,


Convergence Pharmaceuticals Successfully Launched out of GSK to Focus on Novel High Value Analgesics

Convergence Pharmaceuticals Ltd, a new company focused on the development of novel and high value analgesic medicines, was officially launched and has successfully raised $35.4 million (£22.4 million) in Series A financing from a syndicate of leading European and US life science investors. Convergence Pharmaceuticals is an independent biotechnology company that has acquired clinical assets from GlaxoSmithKline ("GSK").


Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business

Mylan Inc. (Nasdaq: MYL) has announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash.


Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.

Astellas Pharma Inc.Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, have entered into a definitive merger agreement under which Astellas will acquire OSI.


ratiopharm to become the hub for Teva's European growth strategy

Teva Pharmaceutical Industries Ltd.The ratiopharm Group gets a new owner. Subsequent to an extensive bidding process, the Israel-based company Teva Pharmaceutical Industries Ltd. is going to acquire the Ulm based company from Merckle Group's VEM asset management. The agreed enterprise value is € 3.625 billion.


Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results

Johnson & Johnson has announced sales for the year 2008 of $63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6% and a positive currency impact of 5.1%. Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007.


Johnson & Johnson Announces Definitive Agreement to Acquire Omrix

Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, have announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer.


World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]